On Tuesday, Shares of Prologis Inc (NYSE:PLD), lost -1.46% to $41.30.
Prologis, declared it has accomplished the formerly declared acquisition of a property portfolio from Morris Realty Associates LLC.
This portfolio comprises 3.2 million square feet of Class-A industrial operating and development properties located primarily in northern New Jersey and 2.2 million square feet of retail property. The retail properties are subject to a purchase agreement with associates of Blackstone Real Estate Advisors L.P.
Prologis intends to sell this portion of the portfolio for $374 million, counting the assumption of debt. The transaction with Blackstone is predictable to close in the fourth quarter of 2015, and is subject to lender consents and customary closing conditions.
Prologis Inc. is an independent equity real estate investment trust. It invests in the real estate markets across the globe. The firm engages in the ownership, development, administration, and leasing of industrial distribution and retail properties.
Shares of Williams Partners LP (NYSE:WPZ), declined -4.42% to $32.20, during its last trading session.
Williams and Williams Partners, planned to declare their third-quarter 2015 financial results after the market closes on Wednesday, Oct. 28.
The company and the partnership will host a joint Q&A live webcast on Thursday, Oct. 29, at 9:00 a.m. EDT.
Williams Partners L.P., an energy infrastructure company, focuses on connecting North America’s hydrocarbon resource plays to growing markets for natural gas and natural gas liquids (NGL). It operates in Northeast G&P, Atlantic-Gulf, West, and NGL & Petchem Services segments.
Finally, Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF), ended its last trade with -9.01% loss, and closed at $4.24.
Can-Fite BioPharma Ltd., declared that it has reached definitive agreements with existing institutional investors to receive gross proceeds of about $4.8 million.
In connection with the offering, the Company will issue 1,109,196 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $4.35 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase 40% of an ADS. The warrants have an exercise price of $5.25 per ADS, shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The closing of the offering is predictable to take place on or about October 15, 2015, subject to the satisfaction of customary closing conditions.
“Following our recent $9 million fund raise in September, we are happy that the same institutional investors who take partd in last month’s round have invested again in Can-Fite’s current registered direct offering. We believe this reflects growing confidence in our Company,” stated Can-Fite CEO, Pnina Fishman.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. It offers CF101, which has accomplished Phase II/III clinical trials for the treatment of psoriasis; accomplished Phase II clinical trials for the treatment of rheumatoid arthritis; accomplished Phase I clinical study for the treatment of osteoarthritis; and accomplished Phase I study for the treatment of uveitis, in addition to is in Phase II clinical trials for the treatment of glaucoma or related syndromes of ocular hypertension.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
